227 related articles for article (PubMed ID: 20485168)
1. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Park MS; Ravi V; Araujo DM
Curr Opin Oncol; 2010 Jul; 22(4):351-5. PubMed ID: 20485168
[TBL] [Abstract][Full Text] [Related]
2. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors.
Park MS; Araujo DM
Curr Opin Oncol; 2009 Jul; 21(4):327-31. PubMed ID: 19444101
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management.
Emamaullee JA; Edgar R; Toso C; Thiesen A; Bain V; Bigam D; Kneteman N; Shapiro AM
Liver Transpl; 2010 Feb; 16(2):191-7. PubMed ID: 20104492
[TBL] [Abstract][Full Text] [Related]
4. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
5. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.
Takahashi H; Shibuya M
Clin Sci (Lond); 2005 Sep; 109(3):227-41. PubMed ID: 16104843
[TBL] [Abstract][Full Text] [Related]
6. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
9. [Anti-angiogenesis targeting drugs: a review].
Jia K; Li J
Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
11. The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets?
Stacher E; Gruber-Mösenbacher U; Halbwedl I; Dei Tos AP; Cavazza A; Papotti M; Carvalho L; Huber M; Ermert L; Popper HH
Lung Cancer; 2009 Jul; 65(1):49-55. PubMed ID: 19100646
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
14. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas.
Itakura E; Yamamoto H; Oda Y; Tsuneyoshi M
J Surg Oncol; 2008 Jan; 97(1):74-81. PubMed ID: 18041747
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
17. VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: A case series with review of the literature.
Telli TA; Okten IN; Tuylu TB; Demircan NC; Arikan R; Alan O; Ercelep O; Ones T; Yildirim AT; Dane F; Yumuk PF
Curr Probl Cancer; 2020 Oct; 44(5):100568. PubMed ID: 32201052
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.
Folpe AL; Veikkola T; Valtola R; Weiss SW
Mod Pathol; 2000 Feb; 13(2):180-5. PubMed ID: 10697276
[TBL] [Abstract][Full Text] [Related]
20. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.
Tokuyama W; Mikami T; Masuzawa M; Okayasu I
Hum Pathol; 2010 Mar; 41(3):407-14. PubMed ID: 19913279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
